Vaxcyte (PCVX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Strategic focus and market opportunity

• Pneumococcal conjugate vaccines are the primary focus, addressing a historically significant cause of death with improved technology for broader coverage and immunogenicity.

• The market is valued at $8 billion and is expected to grow, especially as adult vaccination rates increase globally.

• Expansion beyond the U.S. is a priority, with evolving recommendations for adult vaccination in multiple countries and a new Chief Commercial Officer to guide global strategy.

• Selective commercialization and partnerships are planned to maximize reach, particularly for the infant segment.

• The adult market is projected to reach $4–5 billion, with catch-up cohorts and expanded age recommendations driving growth.

Clinical development and regulatory strategy

• Phase 3 program for VAX-31 launched after strong phase 2 data, showing improved immune responses with expanded serotype coverage.

• The pivotal OPUS-1 study involves 4,000 adults aged 50+, comparing VAX-31 to current standards with higher non-inferiority thresholds.

• Additional studies include co-administration with flu vaccines and evaluation in previously vaccinated adults, with a manufacturing consistency study planned.

• Regulatory standards have shifted from a 0.5 to 0.67 non-inferiority threshold, but historical predictability in this vaccine class is high.

• The pivotal study includes both 50–64 and 65+ age groups, reflecting recent changes in universal vaccination recommendations.

Competitive landscape and product differentiation

• VAX-31 aims to surpass current vaccines (Prevnar 20 and CAPVAXIVE) by covering both older and newer serotypes, offering a singular, broad-spectrum solution.

• CAPVAXIVE has gained rapid market share due to broader coverage, but VAX-31 is positioned to become the next preferred recommendation if data supports its profile.

• The pivotal study compares VAX-31 to both competitors across overlapping and unique serotypes, with analytical flexibility for trade-offs in immune response.

• FDA acknowledges the trade-off between coverage and immune response, with VAX-31 data providing reassurance.

• Market share shifts are driven by coverage breadth, and VAX-31 could become the next incremental recommendation.